- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 217/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Patent holdings for IPC class C07D 217/26
Total number of patents in this class: 398
10-year publication summary
|
28
|
27
|
19
|
30
|
25
|
22
|
21
|
28
|
20
|
14
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| FibroGen, Inc. | 139 |
22 |
| Bristol-myers Squibb Company | 4833 |
19 |
| Bayer Pharma AG | 1048 |
8 |
| Astellas Pharma Inc. | 1053 |
7 |
| BASF SE | 21083 |
6 |
| City of Hope | 1006 |
6 |
| Abbvie Inc. | 1813 |
5 |
| Takeda Pharmaceutical Company Limited | 2719 |
5 |
| Bausch + Lomb Ireland Limited | 714 |
5 |
| Novartis AG | 10635 |
4 |
| Bayer AG | 3385 |
4 |
| Cytokinetics, Inc. | 280 |
4 |
| Dr. Reddy's Laboratories Limited | 555 |
4 |
| Lupin Limited | 432 |
4 |
| Tongli Biomedical Co., Ltd | 31 |
4 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2897 |
4 |
| H. Lundbeck A/S | 1237 |
4 |
| Cytosinlab Therapeutics Co., Ltd. | 15 |
4 |
| F. Hoffmann-La Roche AG | 7931 |
3 |
| Sandoz AG | 1418 |
3 |
| Other owners | 273 |